US 12,331,307 B2
Modified immunization vectors
Giuseppe Pantaleo, Lausanne (CH); Thierry Calandra, Lausanne (CH); Alexandre Harari, Lausanne (CH); Thierry Roger, Lausanne (CH); Mariano Esteban, Madrid (ES); Bertram Jacobs, Phoenix, AZ (US); Karen Kibler, Phoenix, AZ (US); Cornelius Melief, Leiden (NL); Rafick-Pierre Sekaly, Montreal (CA); Elias Haddad, Montreal (CA); and James Tartaglia, Toronto (CA)
Assigned to ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY, Phoenix, AZ (US); CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, Madrid (ES); and IPPOX Foundation, Lausanne (CH)
Filed by Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Arizona State University, Phoenix, AZ (US); Consejo Superior De Investigaciones Cientificas, Madrid (ES); and IPPOX Foundation, Lausanne (CH)
Filed on Apr. 28, 2022, as Appl. No. 17/732,141.
Application 17/732,141 is a continuation of application No. 16/513,757, filed on Jul. 17, 2019, granted, now 11,345,928.
Application 16/513,757 is a continuation of application No. 15/289,297, filed on Oct. 10, 2016, granted, now 10,370,679, issued on Aug. 6, 2019.
Application 15/289,297 is a continuation of application No. 13/266,282, granted, now 9,670,506, issued on Jun. 6, 2017, previously published as PCT/US2010/032966, filed on Apr. 29, 2010.
Claims priority of provisional application 61/174,024, filed on Apr. 30, 2009.
Prior Publication US 2023/0009041 A1, Jan. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 39/12 (2006.01); A61K 39/275 (2006.01); A61K 39/295 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 39/275 (2013.01); A61K 39/295 (2013.01); A61K 39/12 (2013.01); A61K 2039/5256 (2013.01); A61K 49/00 (2013.01); C12N 2710/24143 (2013.01)] 19 Claims
 
1. A recombinant NYVAC vector comprising within its genome a polynucleotide encoding:
a) C7L (SEQ ID NO: 17) and K1L (SEQ ID NO: 27), wherein the C7L (SEQ ID NO: 17) and K1L (SEQ ID NO: 27) coding sequences are adjacent to one another in the genome; or,
b) C7L (SEQ ID NO. 17) and K1L (SEQ ID NO. 27), and optionally at least one of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), and M2L (SEQ ID NO. 25); wherein the C7L (SEQ ID NO. 17) and the and K1L (SEQ ID NO. 27) are positioned adjacent to C8L and K2L, respectively, in the genome; or,
c) a polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17), a polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27), and at least one polypeptide having at least approximately 90% identity to a polypeptide selected from the group consisting of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), and M2L (SEQ ID NO. 25), wherein the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17) is positioned adjacent to the C8L coding sequence in the genome and the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27) is positioned adjacent to the K2L coding sequence in the genome; or,
d) a first polypeptide having at least about 90% identity to C7L (SEQ ID NO: 17), and a second polypeptide having at least about 90% identity to K1L (SEQ ID NO: 27), wherein polynucleotides encoding the first polypeptide and second polypeptide are positioned adjacent to one another in the genome;
wherein the recombinant NYVAC vector further comprises:
one or more modifications of at least one polynucleotide encoding B8R (SEQ ID NO. 1) that renders the vector unable to express B8R (SEQ ID NO: 1); and/or,
one or more modifications of at least one polynucleotide encoding B19R (SEQ ID NO. 3) that renders the vector unable to express B19R.